Abstract:The neurotoxicity associated to the anticancer treatments has received a growing body of interest in the recent years. The development of innovating therapies over the last 20years has led to the emergence of new toxicities. Their diagnosis and management can be challenging in the clinical practice and further research is warranted to improve the understanding of their pathogenic mechanisms. Conventional treatments as radiation therapy and chemotherapy are associated to well-known and under exploration emerging central nervous system (CNS) and peripheral nervous system (PNS) toxicities. The identification of the risk factors and a better understanding of their pathogeny through a "bench to bedside and back again" approach, are the first steps towards the development of toxicity mitigation strategies. New imaging techniques and biological explorations are invaluable for their diagnosis. Immunotherapies have changed the cancer treatment paradigm from tumor cell centered to immune modulation towards an efficient anticancer immune response. The use of the immune checkpoints inhibitors (ICI) and CAR-T cells (chimeric antigen receptor) lead to an increase in the incidence of immune-mediated toxicities and new challenges in the neurological patient's management. The neurological ICI related adverse events (n-irAE) are rare but potentially severe and may present with both CNS and PNS involvement. The most frequent and well characterized, from a clinical and biological standpoint, are the PNS phenotypes: myositis and polyradiculoneuropathy, but the knowledge on CNS phenotypes and their treatments is expanding. The n-irAE management requires a good balance between dampening the autoimmune toxicity without impairing the anticancer immunity. The adoptive cell therapies as CAR-T cells, a promising anticancer strategy, trigger cellular activation and massive production of proinflammatory cytokines inducing frequent and sometime severe toxicity known as cytokine release syndrome and immune effector cell-associated neurologic syndrome. Their management requires a close partnership between oncologist-hematologists, neurologists, and intensivists. The oncological patient's management requires a multidisciplinary clinical team (oncologist, neurologist and paramedical) as well as a research team leading towards a better understanding and a better management of the neurological toxicities.

Neurologic Complications in Adult Cancer Survivorship

Neurological complications in oncology and their monitoring and management in clinical practice: a narrative review

Management of Neurologic Complications in Patients with Brain and Spine Tumors

Neurologic Complications of Therapy

Neuropsychological rehabilitation for survivors of childhood and adolescent brain tumors: a view of the past and a vision for a promising future

Late and Long-Term Treatment-Related Effects and Survivorship for Head and Neck Cancer Patients

Neurological complications of modern radiotherapy for head and neck cancer

Long-term Survivors of Childhood Brain Tumors: Impact on General Health and Quality of Life

Advances in treatments of patients with classical and emergent neurological toxicities of anticancer agents

Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship

Incidence of Neurologic Deficits and Rehabilitation of Patients with Brain Tumors

Impact of Risk-Based therapy on late morbidity and mortality in neuroblastoma survivors: a report from the childhood cancer survivor study

Ncmp-27. Neurological Complications In Lung Cancer Therapies: Unveiling The Elevated Risks In Chemotherapy And Targeted Treatment Approaches

Cognitive impairment after cancer treatment: mechanisms, clinical characterization, and management

Neuropsychological Late Effects and Quality-of-Life Outcomes in Pediatric Brain Tumor Survivors: Role of Pediatric Neurologists in Monitoring and Management

Neurological complications of cancer immunotherapy

Long-term neurocognitive function after whole-brain radiotherapy in patients with melanoma brain metastases in the era of immunotherapy

Postacute Cognitive Rehabilitation for Adult Brain Tumor Patients

A Systematic Review on the Potential Acceleration of Neurocognitive Aging in Older Cancer Survivors

Living with a central nervous system (CNS) tumor: findings on long-term survivorship from the NIH Natural History Study

Neuromuscular complications following targeted therapy in cancer patients: beyond the immune checkpoint inhibitors. Case reports and review of the literature